Literature DB >> 8572741

Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials.

N Ruperto1, E H Giannini.   

Abstract

OBJECTIVE: To estimate the degree of redundancy among articular response variables used routinely in juvenile chronic arthritis (JCA) clinical trials.
METHODS: We obtained data from a large, computerised databank holding information from multiple clinical trials in children with JCA to determine Pearson correlation coefficients for changes from baseline values in articular response variables. All 508 JCA patients who entered the analysis of efficacy of the original trials were included in the present study. An r value of 0.7 or greater was considered evidence of colinearity.
RESULTS: When changes in joint counts of articular manifestations were compared with changes in the respective severity scores (for example swollen joint count versus swelling severity score), the r values were always > or = 0.7. Three articular response variables related to the assessment of pain are all highly correlated with each other. The number of joints with active arthritis was correlated with the number of joints with swelling and the swelling score. Change in the overall severity score was highly correlated (r > or = 0.7) with change in nearly all articular response variables.
CONCLUSIONS: Many endpoints reported in JCA trials are redundant, especially counts and scores of the same articular measure. Eliminating redundant variables would provide the same information with less complexity, and decrease the probability of statistical error and ambiguous results.

Entities:  

Mesh:

Year:  1996        PMID: 8572741      PMCID: PMC1010087          DOI: 10.1136/ard.55.1.73

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  Which traditional measures should be used in rheumatoid arthritis clinical trials?

Authors:  J J Anderson; D T Felson; R F Meenan; H J Williams
Journal:  Arthritis Rheum       Date:  1989-09

Review 2.  OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction.

Authors:  P Tugwell; M Boers
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

3.  Validity of single variables and indices to measure disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M van 't Hof; P L van Riel; L B van de Putte
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

4.  Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data.

Authors:  E H Giannini; E J Brewer
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

5.  Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design.

Authors:  E J Brewer; E H Giannini
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

6.  Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.

Authors:  E H Giannini; E J Brewer; N Kuzmina; A Shaikov; B Wallin
Journal:  Arthritis Rheum       Date:  1990-04

7.  Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group.

Authors:  E D Silverman; G D Cawkwell; D J Lovell; R M Laxer; T J Lehman; M H Passo; L S Zemel; E H Giannini
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

8.  Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.

Authors:  E J Brewer; E H Giannini; N Kuzmina; L Alekseev
Journal:  N Engl J Med       Date:  1986-05-15       Impact factor: 91.245

9.  Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials.

Authors:  D T Felson
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

10.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06
View more
  5 in total

Review 1.  Criteria to define response to therapy in paediatric rheumatic diseases.

Authors:  Nicolino Ruperto; Angela Pistorio; Angelo Ravelli; Rachana Hasija; Dinara Guseinova; Giovanni Filocamo; Erkan Demirkaya; Clara Malattia; Alberto Martini
Journal:  Eur J Clin Pharmacol       Date:  2010-11-20       Impact factor: 2.953

Review 2.  A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

Authors:  E H Davies; R Surtees; C DeVile; I Schoon; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

3.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

4.  Implementation of musculoskeletal ultrasonography in detection of early juvenile idiopathic arthritis.

Authors:  Ayman F Darwish; Faten M Ismael; Abdou Ell-Laban; Ahmed Hamed; Moustafa Abdel Kader; Ashraf Osman
Journal:  Eur J Radiol Open       Date:  2016-11-21

Review 5.  Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology.

Authors:  Hermine I Brunner; Lisa G Rider; Daniel J Kingsbury; Dominic Co; Rayfel Schneider; Ellen Goldmuntz; Karen B Onel; Edward H Giannini; Daniel J Lovell
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-11       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.